Gene therapy for cancer and metastatic disease

Expert Reviews in Molecular Medicine

Volumn 5, Issue 17, 2003, Pages

  Kesmodel, Susan B ^a   Spitz, Francis R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anti angiogenic agents; cancer; gene therapy; gene therapy vectors; immunopotentiation; metastatic disease; mutation compensation; suicide gene therapy; viral oncolysis

Indexed keywords

ANIMAL; GENE THERAPY; GENE VECTOR; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW;

ANIMALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 22544482819     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399403006380     Document Type: Review

References (127)

1. Jemal, A. et al. (2002) Cancer statistics, 2002. CA Cancer J Clin 52, 23-47, PubMed: 21672542 (Pubitemid 34110469)
2. Bishop, J.M. (1987) The molecular genetics of cancer. Science 235, 305-311, PubMed: 87094203 (Pubitemid 17232555)
3. Weinberg, R.A. (1996) How cancer arises. Sci Am 275, 62-70, PubMed: 96327166
4. Nishikawa, M. and Huang, L. (2001) Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 12, 861-870, PubMed: 21280921 (Pubitemid 32681851)
5. Li, S. and Huang, L. (2000) Nonviral gene therapy: promises and challenges. Gene Ther 7, 31-34, PubMed: 20146294 (Pubitemid 30077146)
6. Farhood, H. et al. (1994) Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann N Y Acad Sci 716, 23-34; discussion 34-25, PubMed: 94295994
7. Robbins, P.D., Tahara, H. and Ghivizzani, S.C. (1998) Viral vectors for gene therapy. Trends Biotechnol 16, 35-40, PubMed: 98131005 (Pubitemid 28064816)
8. Kay, M.A., Glorioso, J.C. and Naldini, L. (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7, 33-40, PubMed: 21065270 (Pubitemid 32095639)
9. Wolff, J.A. et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468, PubMed: 90208305
10. Nabel, G.J. et al. (1996) Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 93, 15388-15393, PubMed: 97140340 (Pubitemid 27009610)
11. Sacco, M.G. et al. (2000) Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 60, 2660-2665, PubMed: 20283285 (Pubitemid 30318241)
12. Hortobagyi, G.N. et al. (2001) Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19, 3422-3433, PubMed: 21348069 (Pubitemid 32642196)
13. Nabel, E.G. et al. (1992) Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 3, 649-656, PubMed: 93129664
14. Kirn, D., Martuza, R.L. and Zwiebel, J. (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7, 781-787, PubMed: 21326518 (Pubitemid 32691631)
15. Marshall, E. (2002) Clinical research. Gene therapy a suspect in leukemia-like disease. Science 298, 34-35, PubMed: 22251323
16. Mineta, T. et al. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938-943, PubMed: 96071601
17. During, M.J. et al. (1994) Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399-1403, PubMed: 95064020
18. Latchman, D.S. (2001) Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene 264, 1-9, PubMed: 21142387 (Pubitemid 32195481)
19. Lachmann, R.H. and Efstathiou, S. (1997) The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Mol Med Today 3, 404-411, PubMed: 97448281 (Pubitemid 28127960)
20. Danthinne, X. and Imperiale, M.J. (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7, 1707-1714, PubMed: 20534462
21. Yang, Y. and Wilson, J.M. (1995) Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 155, 2564-2570, PubMed: 95378679
22. Ponnazhagan, S. et al. (2001) Adeno-associated virus for cancer gene therapy. Cancer Res 61, 6313-6321, PubMed: 21413528 (Pubitemid 32783229)
23. Monahan, P.E. and Samulski, R.J. (2000) Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 6, 433-440, PubMed: 20528777
24. Nielsen, L.L. and Maneval, D.C. (1998) P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5, 52-63, PubMed: 98135834 (Pubitemid 128639991)
25. Hollstein, M. et al. (1991) p53 mutations in human cancers. Science 253, 49-53, PubMed: 91289156
26. Seth, P. (2000) Pre-clinical studies with tumor suppressor genes. Adv Exp Med Biol 465, 183-192, PubMed: 20270923 (Pubitemid 32193334)
27. Spitz, F.R. et al. (1996) In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 16, 3415-3422, PubMed: 97194762 (Pubitemid 27084991)
28. Densmore, C.L. et al. (2001) Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 8, 619-627, PubMed: 21476951 (Pubitemid 32912235)
29. Eastham, J.A. et al. (2000) Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 164, 814-819, PubMed: 20411379 (Pubitemid 30637639)
30. Clayman, G.L. et al. (1998) Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16, 2221-2232, PubMed: 98289464 (Pubitemid 28265061)
31. Swisher, S.G. et al. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91, 763-771, PubMed: 99258658 (Pubitemid 29239055)
32. Bookstein, R. et al. (1996) p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Semin Oncol 23, 66-77, PubMed: 96181905 (Pubitemid 26087990)
33. Havlik, R. et al. (2002) Gene therapy for liver metastases. Semin Oncol 29, 202-208, PubMed: 21948306 (Pubitemid 34297292)
34. Mujoo, K. et al. (1996) Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12, 1617-1623, PubMed: 96201641 (Pubitemid 26146285)
35. Zwacka, R.M. and Dunlop, M.G. (1998) Gene therapy for colon cancer. Hematol Oncol Clin North Am 12, 595-615, PubMed: 98348725 (Pubitemid 28347556)
36. Habib, N.A. et al. (1999) A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 10, 2019-2034, PubMed: 99394512 (Pubitemid 29387916)
37. Deshane, J. et al. (1995) Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 59, 8-14, PubMed: 96016292
38. Ellouk-Achard, S. et al. (1998) Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense c-DNA. J Hepatol 29, 807-818, PubMed: 99049666 (Pubitemid 28505939)
39. Hung, M.C., Hortobagyi, G.N. and Ueno, N.T. (2000) Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol 465, 171-180, PubMed: 20270922 (Pubitemid 32193333)
40. Hortobagyi, G.N., Hung, M.C. and Lopez-Berestein, G. (1998) A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther 9, 1775-1798, PubMed: 98386042
41. Alvarez, R.D. et al. (2000) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 6, 3081-3087, PubMed: 20410754 (Pubitemid 30637731)
42. Rigg, A. and Sikora, K. (1997) Genetic prodrug activation therapy. Mol Med Today 3, 359-366, PubMed: 97415057 (Pubitemid 28119271)
43. Huber, B.E. et al. (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91, 8302-8306, PubMed: 94336734
44. Freeman, S.M. et al. (1993) The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53, 5274-5283, PubMed: 94036810
45. Uckert, W. et al. (1998) Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 9, 855-865, PubMed: 98241064 (Pubitemid 28197372)
46. Nagy, H.J. et al. (2000) Suicide gene therapy of ovarian cancer: an experimental study in rats using retroviral-mediated transfer of herpes simplex virus thymidine kinase gene. Anticancer Res 20, 4633-4638, PubMed: 21076753 (Pubitemid 32141829)
47. Sterman, D.H. et al. (1998) Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9, 1083-1092, PubMed: 98268435 (Pubitemid 28236516)
48. Sterman, D.H., Kaiser, L.R. and Albelda, S.M. (1998) Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 12, 553-568, PubMed: 98348723 (Pubitemid 28347554)
49. Gnant, M.F. et al. (1999) Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. Ann Surg 230, 352-360; discussion 360-351, PubMed: 99421225
50. Smythe, W.R. et al. (1995) Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 222, 78-86, PubMed: 95344282
51. Elshami, A.A. et al. (1996) Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7, 141-148, PubMed: 96380152 (Pubitemid 26044833)
52. Topf, N. et al. (1998) Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 5, 507-513, PubMed: 98276759 (Pubitemid 28200643)
53. Koyama, F. et al. (2000) Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 7, 1015-1022, PubMed: 20371872 (Pubitemid 30483481)
54. Chung-Faye, G.A. et al. (2001) In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 8, 1547-1554, PubMed: 21560682 (Pubitemid 33061893)
55. Stopeck, A.T. et al. (2001) Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 7, 2285-2291, PubMed: 21381723 (Pubitemid 32751626)
56. Hersh, E.M. and Stopeck, A.T. (1997) Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res 3, 2623-2629, PubMed: 99163408 (Pubitemid 28133117)
57. Wojtowicz-Praga, S. (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20, 165-177, PubMed: 97325401 (Pubitemid 28011544)
58. Ettinghausen, S.E. and Rosenberg, S.A. (1995) Immunotherapy and gene therapy of cancer. Adv Surg 28, 223-254, PubMed: 95185382
59. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384, PubMed: 21256223 (Pubitemid 32467048)
60. Mitra, R., Singh, S. and Khar, A. (2003) Antitumour immune responses. Exp. Rev. Mol. Med. 5, DOI: 10.1017/S1462399403005623
61. Rosenberg, S.A. (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287, PubMed: 99219178 (Pubitemid 29165283)
62. Wang, J. et al. (2001) Gene gun-mediated oral mucosal transfer of interleukin 12 cDNA coupled with an irradiated melanoma vaccine in a hamster model: successful treatment of oral melanoma and distant skin lesion. Cancer Gene Ther 8, 705-712, PubMed: 21543318 (Pubitemid 32983126)
63. Mastrangelo, M.J. et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6, 409-422, PubMed: 99433670 (Pubitemid 129667814)
64. Kusumoto, M. et al. (2001) Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 50, 373-381, PubMed: 21530814 (Pubitemid 32835347)
65. Kang, W.K. et al. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 12, 671-684, PubMed: 21319759
66. Nanni, P. et al. (1998) Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 58, 1225-1230, PubMed: 98175562 (Pubitemid 28183212)
67. Sun, Y. et al. (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5, 481-490, PubMed: 98276756 (Pubitemid 28200640)
68. Nagai, E. et al. (1998) Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunol Immunother 47, 72-80, PubMed: 98440051 (Pubitemid 28442706)
69. Wang, R.F. and Rosenberg, S.A. (1999) Human tumor antigens for cancer vaccine development. Immunol Rev 170, 85-100, PubMed: 20032578 (Pubitemid 29490747)
70. Song, W. et al. (1997) Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186, 1247-1256, PubMed: 97477408 (Pubitemid 27469020)
71. Schutz, A. et al. (2001) Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer Gene Ther 8, 655-661, PubMed: 21476955 (Pubitemid 32912239)
72. Rosenberg, S.A. et al. (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90, 1894-1900, PubMed: 99077463 (Pubitemid 29014223)
73. Marshall, J.L. et al. (2000) Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti- carcinoembryonic antigen immune responses. J Clin Oncol 18, 3964-3973, PubMed: 20551342
74. Wang, Z. et al. (2001) Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther 8, 751-758, PubMed: 21543323 (Pubitemid 32983131)
75. Takahashi, S. et al. (2001) Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 8, 378-387, PubMed: 21369498 (Pubitemid 32685645)
76. Noguchi, M. et al. (2001) Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 8, 421-429, PubMed: 21389184 (Pubitemid 32757959)
77. Kirn, D.H. and McCormick, F. (1996) Replicating viruses as selective cancer therapeutics. Mol Med Today 2, 519-527, PubMed: 97168176 (Pubitemid 126376968)
78. Martuza, R.L. et al. (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856, PubMed: 91227914 (Pubitemid 121000529)
79. Bischoff, J.R. et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376, PubMed: 96436550 (Pubitemid 26353341)
80. Heise, C. et al. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3, 639-645, PubMed: 97319587 (Pubitemid 27264973)
81. Ries, S.J. et al. (2000) Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 6, 1128-1133, PubMed: 20473283
82. Vollmer, C.M. et al. (1999) p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 59, 4369-4374, PubMed: 99413495 (Pubitemid 29418756)
83. Ganly, I. et al. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6, 798-806, PubMed: 20203743 (Pubitemid 30159332)
84. Nemunaitis, J. et al. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60, 6359-6366, PubMed: 20552161
85. Walker, J.R. et al. (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10, 2237-2243, PubMed: 99426542 (Pubitemid 29416302)
86. Coukos, G. et al. (2000) Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 7, 275-283, PubMed: 20231406 (Pubitemid 30194563)
87. Kooby, D.A. et al. (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). Faseb J 13, 1325-1334, PubMed: 99357713 (Pubitemid 29382501)
88. Rodriguez, R. et al. (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57, 2559-2563, PubMed: 97349049 (Pubitemid 27283756)
89. Kurihara, T. et al. (2000) Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106, 763-771, PubMed: 20453313
90. Hallenbeck, P.L. et al. (1999) A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 10, 1721-1733, PubMed: 99355171 (Pubitemid 29328216)
91. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186, PubMed: 72008493
92. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31, PubMed: 96071368
93. Folkman, J. (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3, 65-71, PubMed: 92329736
94. Folkman, J. (1996) Fighting cancer by attacking its blood supply. Sci Am 275, 150-154, PubMed: 96327182
95. Beckner, M.E. (1999) Factors promoting tumor angiogenesis. Cancer Invest 17, 594-623, PubMed: 20060352
96. Feldman, A.L. and Libutti, S.K. (2000) Progress in antiangiogenic gene therapy of cancer. Cancer 89, 1181-1194, PubMed: 20458923
97. Goldman, C.K. et al. (1998) Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95, 8795-8800, PubMed: 98337995 (Pubitemid 28350568)
98. Kong, H.L. et al. (1998) Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9, 823-833, PubMed: 98241061
99. Millauer, B. et al. (1996) Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56, 1615-1620, PubMed: 96181313 (Pubitemid 26104026)
100. Kuo, C.J. et al. (2001) Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98, 4605-4610, PubMed: 21192675 (Pubitemid 32295023)
101. O'Reilly, M.S. et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328, PubMed: 95042728 (Pubitemid 24324921)
102. Cao, Y. et al. (1998) Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101, 1055-1063, PubMed: 98153232 (Pubitemid 28125284)
103. Rodolfo, M. et al. (2001) Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther 8, 491-496, PubMed: 21389192 (Pubitemid 32737835)
104. O'Reilly, M.S. et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285, PubMed: 97160848 (Pubitemid 28015876)
105. Feldman, A.L. et al. (2001) Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst 93, 1014-1020, PubMed: 21331886 (Pubitemid 32677401)
106. Sauter, B.V. et al. (2000) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 97, 4802-4807, PubMed: 20243776 (Pubitemid 30238638)
107. Kwong, Y.L. et al. (1997) Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer. Chest 112, 1332-1337, PubMed: 98033300
108. Lechanteur, C. et al. (2000) Combined suicide and cytokine gene therapy for peritoneal carcinomatosis. Gut 47, 343-348, PubMed: 20400365
109. Hayashi, S. et al. (1997) Inhibition of establishment of hepatic metastasis in mice by combination gene therapy using both herpes simplex virus-thymidine kinase and granulocyte macrophage-colony stimulating factor genes in murine colon cancer. Cancer Gene Ther 4, 339-344, PubMed: 98072901 (Pubitemid 127667125)
110. Spitz, F.R. et al. (1996) Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2, 1665-1671, PubMed: 99035194 (Pubitemid 26356349)
111. Khil, M.S. et al. (1996) Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 2, 53-57, PubMed: 99034992 (Pubitemid 26042179)
112. Sasaki, R. et al. (2001) Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 51, 1336-1345, PubMed: 21585851 (Pubitemid 33116329)
113. You, L., Yang, C.T. and Jablons, D.M. (2000) ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 60, 1009-1013, PubMed: 20168634 (Pubitemid 30129538)
114. Khuri, F.R. et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6, 879-885, PubMed: 20392577 (Pubitemid 30644745)
115. Son, K. (1997) Cisplatin-based interferon gamma gene therapy of murine ovarian carcinoma. Cancer Gene Ther 4, 391-396, PubMed: 98072908 (Pubitemid 127667132)
116. Weinrib, L. et al. (2001) Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and-negative nasopharyngeal carcinoma. Cancer Gene Ther 8, 352-360, PubMed: 21369495 (Pubitemid 32685642)
117. Nishizaki, M. et al. (2001) Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 7, 2887-2897, PubMed: 21439144 (Pubitemid 32911399)
118. Singh, R.K. et al. (1995) Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92, 4562-4566, PubMed: 95273403
119. Tada, H. et al. (2001) Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 108, 83-95, PubMed: 21329135 (Pubitemid 32634925)
120. Verma, I.M. (2000) Gene therapy: public education. Mol Ther 2, 177, PubMed: 20442623
121. Webb, A. et al. (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137-1141, PubMed: 97267683 (Pubitemid 27168548)
122. Jansen, B. et al. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733, PubMed: 20544370
123. Wu, R.S. et al. (2001) Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother 50, 229-240, PubMed: 21390644 (Pubitemid 32662526)
124. Plautz, G.E. et al. (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90, 4645-4649, PubMed: 93281635 (Pubitemid 23148962)
125. Gleich, L.L. et al. (1998) Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 124, 1097-1104, PubMed: 98447082 (Pubitemid 28471598)
126. Tzai, T.S. et al. (1998) Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res 18, 1585-1589, PubMed: 98338091
127. Chung-Faye, G.A. et al. (2000) Gene therapy strategies for colon cancer. Mol Med Today 6, 82-87, PubMed: 20119522